血液筛检市场规模（按类型、技术、最终用户、地区、范围和预测）

血液筛检市场规模及预测

2023 年血液筛检市场规模价值 27 亿美元，预计到 2031 年将达到 54 亿美元，预测期内（2024-2031 年）的复合年增长率为 8.6%。

血液筛检是分析血液样本以识别感染、疾病和失调的过程。识别爱滋病毒、肝炎等病毒和其他血液传染，确保输血安全并儘早发现以进行治疗，为整体公共卫生和疾病预防工作做出贡献。

血液筛检可以检测出爱滋病毒、肝炎和疟疾等传染病，从而实现安全输血。它可以检测糖尿病和高胆固醇等慢性疾病，帮助早期诊断癌症，监测器官功能，并透过检测多种疾病的风险因素来促进预防保健，从而改善整体公共卫生和安全。

血液筛检的未来应用将改善早期疾病识别，并为癌症和心血管疾病等疾病提供个人化的治疗策略。先进技术正在提高识别基因标记和传染病的准确性，从而实现更好的预防保健、慢性病监测以及更安全的输血和器官移植。

血液筛检市场动态

影响血液筛检市场的关键市场动态

主要市场驱动因子

增加捐血量：

增加捐血量：全球捐血和输血量的增加对有效的血液筛检方法产生了需求。

传染病发生率不断上升：

爱滋病毒、肝炎和寨卡病毒等传染病的发生率不断上升，需要严格的血液筛检规程。

技术进步：

核酸扩增检验（NAT）和次世代定序（NGS）等血液筛检技术的创新正在提高血液检测的准确性和效率。

政府措施：

政府的支持性政策和对血液安全计划的资助正在推动市场成长。

民族意识：

大众对血液安全重要性的认识不断提高，促进了市场扩张。

主要问题：

筛检成本高：

先进筛检技术的高成本可能会成为其采用的障碍，尤其是在发展中国家。

监理的严格程度：

严格的监管要求和新筛选技术的冗长的审批流程可能会阻碍市场成长。

限制低收入地区的接取：

低收入地区有限的基础设施和资源限制了先进血液筛检方法的实施。

主要趋势：

自动化血液筛检：

将自动化融入血液筛检过程可提高吞吐量并减少人工错误。

人工智慧的采用：

人工智慧和机器学习在血液筛检的数据分析和解释中的应用越来越多，从而提高了诊断的准确性。

即时检定：

血液筛检中即时诊断检测 (POCT) 的兴起提供了快速可靠的结果，尤其是在偏远和服务不足的地区。

血液筛检市场的区域分析

北美

根据经过验证的市场研究，北美预计将主导血液筛检市场。

这一优势源于对输血的高需求、先进的医疗保健基础设施以及 Grifols、雅培实验室和 Bio-Rad 实验室等知名企业的存在。

此外，严格的监管框架和公众对血液安全的认识也是北美在市场上占据领先地位的因素。

亚太地区

根据 Verified Market Research 的调查，亚太地区是血液筛检市场成长最快的地区。

预计亚太地区将见证血液筛检市场的最高成长率。

医疗保健基础设施的扩大、捐血量的增加以及传染病患者病率的上升正在推动市场的成长。

中国、印度和日本等国家正致力于加强血液筛检规程并采用先进技术。

目录

第 1 章：全球血液筛检市场：简介

市场概况
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 主要来源
• 资料来源列表

第四章 全球血液筛检市场展望

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球血液筛检市场（依产品划分）

• 概述
• 试剂和试剂盒
• 设备
• 软体与服务

6. 全球血液筛检市场（依技术划分）

• 概述
• 核酸扩增法
• ELISA 方法
• 快速侦测
• NGS 方法

7. 全球血液筛检市场（依最终用户划分）

• 概述
• 血库
• 医院

第 8 章 全球血液筛检市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第 9 章。

• 概述
• 公司市占率
• 供应商概况
• 主要发展策略

第十章 公司简介

• Grifols
• F. Hoffmann-La Roche
• Abbott Laboratories
• Biomerieux
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers
• Ortho Clinical Diagnostics, Inc.
• Thermo Fisher Scientific, Inc.
• Beckman Coulter
• Becton, Dickinson and Company

第 11 章附录

• 相关研究

Blood Screening Market Size And Forecast

The Blood Screening Market size was valued at USD 2.7 Billion in 2023 and is expected to reachUSD 5.4 Billion in 2031, at aCAGR of 8.6% over the forecast period of 2024 to 2031.

Blood screening is the process of analysing blood samples to identify infections, illnesses and disorders. It identifies viruses such as HIV, hepatitis and other blood-borne infections, ensuring blood transfusion safety and early detection in medical treatments and thereby contributing to overall public health and disease prevention initiatives.

Blood screening detects infectious disorders such as HIV, hepatitis and malaria, allowing for safe blood transfusions. It detects chronic disorders like diabetes and high cholesterol, helps with early cancer diagnosis, monitors organ function, and promotes preventative healthcare by detecting risk factors for numerous illnesses, thereby improving general public health and safety.

Future applications of blood screening will improve early disease identification, allowing for individualized treatment strategies for ailments such as cancer and cardiovascular disease. Advanced technology will improve the accuracy with which genetic markers and infections are identified, allowing for better preventive care, chronic condition monitoring and safer blood transfusions and organ transplantations.

Blood Screening Market Dynamics

The key market dynamics that are shaping the Blood Screening Market include:

Key Market Drivers:

Increasing Blood Donations:

A growing number of blood donations and transfusions worldwide is driving the demand for efficient blood screening methods.

Rising Prevalence of Infectious Diseases:

The increasing incidence of infectious diseases such as HIV, hepatitis, and Zika virus necessitates rigorous blood screening protocols.

Technological Advancements:

Innovations in blood screening technologies, including nucleic acid amplification tests (NAT) and next-generation sequencing (NGS), are enhancing the accuracy and efficiency of blood tests.

Government Initiatives:

Supportive government policies and funding for blood safety programs are propelling the market growth.

Public Awareness:

Increased public awareness about the importance of blood safety is contributing to the market expansion.

Key Challenge:

High Costs of Screening:

The high cost of advanced screening technologies can be a barrier for adoption, especially in developing countries.

Regulatory Stringency:

Stringent regulatory requirements and lengthy approval processes for new screening technologies can hinder market growth.

Limited Access in Low-Income Regions:

Limited infrastructure and resources in low-income regions restrict the implementation of advanced blood screening methods.

Key Trends:

Automation in Blood Screening:

The integration of automation in blood screening processes is improving throughput and reducing manual errors.

Adoption of Artificial Intelligence:

AI and machine learning are being increasingly adopted for data analysis and interpretation in blood screening, enhancing diagnostic accuracy.

Point-of-Care Testing:

The rise of point-of-care testing (POCT) for blood screening is providing quick and reliable results, particularly in remote and underserved areas.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Blood Screening Market Regional Analysis

Here is a more detailed regional analysis of the blood screening market:

North America

According to Verified Market Research, North America is expected to dominate the blood screening market.

This dominance is driven by a high demand for blood transfusions, advanced healthcare infrastructure, and the presence of established players like Grifols, Abbott Laboratories, and Bio-Rad Laboratories.

Additionally, stringent regulatory frameworks and public awareness about blood safety contribute to North America's leading position in the market.

Asia Pacific

According to Verified Market Research, Asia Pacific is fastest growing region in blood screening market.

The Asia Pacific region is expected to witness the highest growth rate in the blood screening market.

The expanding healthcare infrastructure, increasing blood donations, and rising prevalence of infectious diseases are driving the market growth.

Countries like China, India, and Japan are focusing on enhancing their blood screening protocols and adopting advanced technologies.

Blood Screening Market Segmentation Analysis

The Blood Screening Market is segmented on the basis of Type, Application and Geography.

Blood Screening Market, By Type

• Reagents & Kits
• Instruments
• Software & Services

Based on Type, the market is segmented into Reagents & Kits, Instruments and Software & Services. Reagents & kits accounted for the largest market share in the global blood screening market. The growing prevalence of infectious diseases and the rising need for safe blood transfusions have driven the demand for high-quality reagents and kits. These products are essential for detecting pathogens in donated blood, ensuring the safety and reliability of blood transfusions. As healthcare facilities and blood banks prioritize accuracy and efficiency in blood screening processes, the adoption of advanced reagents and kits is significantly increasing. This trend reflects the ongoing efforts to enhance blood safety and the overall quality of healthcare services.

Blood Screening Market, By Technology

• Nucleic Acid Testing (NAT)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Rapid Tests
• Western Blotting

Based on Technology, the market is segmented into Nucleic Acid Testing (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests and Western Blotting. In the Blood Screening Market, Nucleic Acid Testing (NAT) is the dominant technology. NAT is highly favored for its ability to detect viral genetic material at an early stage, significantly reducing the window period during which infections may not be detected by traditional serological methods. This technology ensures a higher level of safety and reliability in blood screening processes, making it crucial for preventing the transmission of infectious diseases through blood transfusions.

Blood Screening Market, By End User

• Blood Banks
• Hospitals
• On the basis of End User, the market is divided into Blood banks and Hospitals. In the blood screening market, blood banks are the dominant end users. Blood banks play a critical role in ensuring the safety and availability of blood for transfusions. They employ rigorous blood screening protocols to detect infectious agents, thereby maintaining the highest standards of blood safety and mitigating the risk of transfusion-transmitted infections.

Blood Screening Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• On the basis of Geography, the Blood Screening Market is classified into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America accounted for the largest market share in the global blood screening market. The region's dominance is attributed to the well-established healthcare infrastructure, high healthcare expenditure, and the presence of key market players. Moreover, the increasing prevalence of chronic diseases and the rising number of surgical procedures requiring blood transfusions have further boosted the demand for blood screening in North America. The region's strong focus on blood safety, coupled with continuous advancements in screening technologies, ensures the growth and sustainability of the blood screening market.

Key Players

• The "Blood Screening Market" study report will provide valuable insight with an emphasis on the global market, including some of the major players in the industry such as
• Abbott Laboratories, Grifols, Bio-Rad Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, Ortho Clinical Diagnostics, Becton Dickinson.

Our market analysis offers detailed information on major players wherein our analysts provide insight into the financial statements of all the major players, product portfolio, product benchmarking and SWOT analysis. The competitive landscape section also includes market share analysis, key development strategies, recent developments, and market ranking analysis of the above-mentioned players globally.

• Blood Screening Market Recent Developments
• In March 2023, Abbott Laboratories introduced a new high-throughput screening system for detecting infectious diseases in donated blood.
• In August 2023, Roche Diagnostics launched a next-generation sequencing platform for comprehensive blood screening.
• In October 2023, Siemens Healthineers entered into a collaboration with a leading blood bank to implement advanced screening technologies.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BLOOD SCREENING MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BLOOD SCREENING MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BLOOD SCREENING MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Reagents & Kits
• 5.3 Instruments
• 5.4 Software & Services

6 GLOBAL BLOOD SCREENING MARKET, BY TECHNOLOGY

• 6.1 Overview
• 6.2 Nucleic Acid Amplification
• 6.3 ELISA
• 6.4 Rapid tests
• 6.5 NGS

7 GLOBAL BLOOD SCREENING MARKET, BY END USER

• 7.1 Overview
• 7.2 Blood Banks
• 7.3 Hospitals

8 GLOBAL BLOOD SCREENING MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL BLOOD SCREENING MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Share
• 9.3 Vendor Landscape
• 9.4 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Grifols
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 F. Hoffmann-La Roche
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Abbott Laboratories
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Biomerieux
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Bio-Rad Laboratories, Inc.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Siemens Healthineers
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Ortho Clinical Diagnostics, Inc.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Thermo Fisher Scientific, Inc.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Beckman Coulter
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Becton, Dickinson and Company
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research